Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038625 | 0.90 | ALDH1A1 (0.53) | MCHR1ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL3038611 | 0.88 | FAAH (0.49) | MCHR1CYP3A4ALDH1A1GAAKDM4E | |
| SCHEMBL13222899 | 0.85 | TACR1 (0.45) | MCHR1ALDH1A1GAATACR1 | |
| SCHEMBL3033257 | 0.85 | ALDH1A1 (0.48) | MCHR1ALDH1A1KDM4ETDP1TACR1 | |
| SCHEMBL3023616 | 0.84 | UBE2M (0.51) | ALDH1A1KCNH2KMT2AMEN1GAA | |
| SCHEMBL3029505 | 0.83 | TACR1 (0.51) | MCHR1ALDH1A1KDM4ETDP1TACR1 | |
| SCHEMBL3038616 | 0.83 | TACR1 (0.47) | MCHR1ALDH1A1KMT2AMEN1TACR1 | |
| SCHEMBL3043043 | 0.82 | MEN1 (0.48) | MCHR1ALDH1A1KMT2AMEN1TACR1 | |
| SCHEMBL3033742 | 0.81 | ALDH1A1 (0.52) | MCHR1ALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL3041690 | 0.80 | CCR2 (0.46) | MCHR1ALDH1A1KMT2AMEN1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | MCHR1 325/4885CYP3A4 1097/4885ALDH1A1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.